Current management of severe homozygous hypercholesterolaemias

Current Opinion in Lipidology

Volumn 15, Issue 4, 2004, Pages 413-422

  Naoumova, Rossi P ^a   Thompson, Gilbert R ^a   Soutar, Anne K ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Aortic valve; Atherosclerosis; Autosomal recessive hypercholesterolaemia; Coronary heart disease; Ezetimibe; Familial hypercholesterolaemia; LDL apheresis; Statins

Indexed keywords

ATORVASTATIN; AVASIMIBE; COMPACTIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

AORTA ATHEROSCLEROSIS; AORTA VALVE; APHERESIS; ATHEROSCLEROSIS; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; DISEASE SEVERITY; FAMILIAL HYPERCHOLESTEROLEMIA; GENE THERAPY; HEART MUSCLE ISCHEMIA; HOMOZYGOSITY; HUMAN; LIVER TRANSPLANTATION; PATIENT MONITORING; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW;

ADOLESCENT; ADULT; APOLIPOPROTEINS B; AZETIDINES; BLOOD COMPONENT REMOVAL; CHILD; CHOLESTEROL; CORONARY DISEASE; FEMALE; GENE THERAPY; GENES, RECESSIVE; HOMOZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; LIVER TRANSPLANTATION; MALE; MODELS, GENETIC; MUTATION; PREGNANCY; TIME FACTORS;

EID: 4043093508     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mol.0000137222.23784.2a     Document Type: Review

References (98)

1. Muller C. Angina pectoris in hereditary xanthomatosis. Arch Intern Med 1939; 64:675-700.
2. Myant NB. The metabolic lesion in familial hypercholesterolaemia. Expos Annu Biochim Med 1977; 33:39-52.
3. Goldstein JL, Brown MS. Binding and degradation of low density lipoproteins by cultured human fibroblasts: comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J Biol Chem 1974; 249:5153-5162.
4. Goldstein JL, Brown MS. The LDL receptor locus and the genetics of familial hypercholesterolemia. Annu Rev Genet 1979; 13:259-289.
5. Vega GL, Grundy SM. In vivo evidence for reduced binding of low density lipoproteins to receptors as a cause of primary moderate hypercholesterolemia. J Clin Invest 1986; 78:1410-1414.
6. Myant NB, Gallagher JJ, Knight BL, et al. Clinical signs of familial hypercholesterolemia in patients with familial defective apolipoprotein B-100 and normal low density lipoprotein receptor function. Arterioscler Thromb 1991; 11:691-703.
7. Khachadurian AK, Uthman SM. Experiences with the homozygous cases of familial hypercholesterolemia: a report of 52 patients. Nutr Metab 1973; 15:132-140.
8. Garcia CK, Wilund K, Arca M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 2001; 292:1394-1398.
9. Eden ER, Patel DD, Sun XM, et al. Restoration of LDL receptor function in cells from patients with autosomal recessive hypercholesterolemia by retroviral expression of ARH1. J Clin Invest 2002; 110:1695-1702.
10. Salen G, Shefer S, Nguyen L, et al. Sitosterolemia. J Lipid Res 1992; 33:945-955.
11. Pullinger CR, Eng C, Salen G, et al. Human cholesterol 7α-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest 2002; 110:109-117.
12. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003; 34:154-156.
13. Soutar AK, Knight BL, Patel DD. Identification of a point mutation in growth factor repeat C of the low density lipoprotein-receptor gene in a patient with homozygous familial hypercholesterolemia that affects ligand binding and intracellular movement of receptors. Proc Natl Acad Sci U S A 1989; 86:4166-4170.
14. Webb JC, Sun XM, Patel DD, et al. Characterization of two new point mutations in the low density lipoprotein receptor genes of an English patient with homozygous familial hypercholesterolemia. J Lipid Res 1992; 33:689-698.
15. Webb JC, Sun XM, McCarthy SN, et al. Characterization of mutations in the low density lipoprotein (LDL)-receptor gene in patients with homozygous familial hypercholesterolemia, and frequency of these mutations in FH patients in the United Kingdom. J Lipid Res 1996; 37:368-381.
16. Feher MD, Webb JC, Patel DD, et al. Cholesterol-lowering drug therapy in a patient with receptor-negative homozygous familial hypercholesterolaemia. Atherosclerosis 1993; 103:171-180.
17. Bourbon M, Fowler AM, Sun XM, Soutar AK. Inheritance of two different alleles of the low-density lipoprotein (LDL)-receptor gene carrying the recurrent Pro664Leu mutation in a patient with homozygous familial hypercholesterolaemia. Clin Genet 1999; 56:225-231.
18. Goldstein J, Hobbs H, Brown M. Familial hypercholesterolemia. In: Valle D, Scriver CR, Beaudet A, et al., editors. The metabolic and molecular bases of inherited disease. 8th ed, vol 2. New York: McGraw Hill; 2001. pp. 2863-2913.
19. Thompson GR. Familial hypercholesterolaemia. In: Wass JAH, Shalet SM, editors. Oxford textbook of endocrinology and diabetes. Oxford: Oxford University Press; 2002. pp. 1545-1552.
20. Durrington P. Dyslipidaemia. Lancet 2003; 362:717-731. A comprehensive review, particularly aimed at clinical readership, summarizing the clinical manifestations of dyslipidaemia and its modern management.
21. Myant NB. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia. Atherosclerosis 1993; 104:1-18.
22. Hansen PS. Familial defective apolipoprotein B-100. Dan Med Bull 1998; 45:370-382.
23. Soutar AK, Naoumova RP, Traub LM. Genetics, clinical phenotype, and molecular cell biology of autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol 2003; 23:1963-1970. This review provides useful information on the history of the genetics of ARH from the first clinical description of the condition, the recognition of a new cellular phenotype and mapping the gene on chromosome 1p35-36.1 to gene cloning. New insights into the role played by ARH protein in gathering the LDL receptor into forming endocytic carrier vesicles are discussed. The ARH clinical phenotype is critically compared to that of homozygous FH patients.
24. Norman D, Sun XM, Bourbon M, et al. Characterization of a novel cellular defect in patients with phenotypic homozygous familial hypercholesterolemia. J Clin Invest 1999; 104:619-628.
25. Arca M, Zuliani G, Wilund K, et al. Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis. Lancet 2002; 359:841-847.
26. Barbagallo CM, Emmanuele G, Cefalu AB, et al. Autosomal recessive hypercholesterolemia in a Sicilian kindred harboring the 432insA mutation of the ARH gene. Atherosclerosis 2003; 166:395-400.
27. Harada-Shiba M, Takagi A, Miyamoto Y, et al. Clinical features and genetic analysis of autosomal recessive hypercholesterolemia. J Clin Endocrinol Metab 2003; 88:2541-2547.
28. Al Kateb H, Bahring S, Hoffmann K, et al. Mutation in the ARH gene and a chromosome 13q locus influence cholesterol levels in a new form of digenic-recessive familial hypercholesterolemia. Circ Res 2002; 90:951-958.
29. Tietge UJ, Genschel J, Schmidt HH. A Q136Stop mutation in the ARH gene causing autosomal recessive hypercholesterolaemia with severely delayed LDL catabolism. J Intern Med 2003; 253:582-583.
30. Cohen JC, Kimmel M, Polanski A, Hobbs HH. Molecular mechanisms of autosomal recessive hypercholesterolemia. Curr Opin Lipidol 2003; 14:121-127. A review article summarizing new findings into the pathophysiology and molecular genetics of ARH, concluding that ARH functions as an adaptor protein that couples the LDL receptor to the endocytic machinery.
31. Schmidt HH, Stuhrmann M, Shamburek R, et al. Delayed low density lipoprotein (LDL) catabolism despite a functional intact LDL-apolipoprotein B particle and LDL-receptor in a subject with clinical homozygous familial hypercholesterolemia. J Clin Endocrinol Metab 1998; 83:2167-2174.
32. Naoumova RP, Neuwirth C, Lee P, et al. Autosomal recessive hypercholesterolaemia: long-term follow up and response to treatment. Atherosclerosis 2004; 174:165-172.
33. Rallidis L, Nihoyannopoulos P, Thompson GR. Aortic stenosis in homozygous familial hypercholesterolaemia. Heart 1996; 76:84-85.
34. Rallidis L, Naoumova RP, Thompson GR, Nihoyannopoulos P. Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia. Heart 1998; 80:583-590.
35. West R, Gibson P, Lloyd J. Treatment of homozygous familial hypercholesterolaemia: an informative sibship. BMJ (Clin Res Ed) 1985; 291:1079-1080.
36. Makino H, Harada-Shiba M. Long-term effect of low-density lipoprotein apheresis in patients with homozygous familial hypercholesterolemia. Therap Apher Dial 2003; 7:397-401. A review article offering a wealth of clinical experience and answers to practical questions.
37. Stefanutti C, Di Giacomo S, Vivenzio A, et al. Low-density lipoprotein apheresis in a patient aged 3.5 years. Acta Paediatr 2001; 90:694-701.
38. Keller C. Indication of low-density lipoprotein apheresis in severe hypercholesterolemia and its atherosclerotic vascular complications: dextran sulfate cellulose low-density lipoprotein apheresis. Therap Apher Dial 2003; 7:345-349. Review article which speculates that reductions in lipoprotein (a) and in LDL oxidation, improvement in procoagulatory state and decreases in adhesion molecules and cytokines induced by LDL apheresis may favourably influence regression of atherosclerosis.
39. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 2003; 111:1795-1803. This review focuses on recent developments in the understanding of the molecular pathogenesis and treatment of monogenic forms of severe hypercholesterolaemia, and some of the implications of these findings for the management of common forms of hypercholesterolaemia.
40. Thompson GR. LDL apheresis. Atherosclerosis 2003; 167:1-13. This comprehensive review summarizes current knowledge on LDL apheresis starting from the history of the procedure and its application as safe and reliable treatment for patients with homozygous FH, where there is clear evidence of benefit. The possibility of widening the indications for LDL apheresis to include patients with post-transplant donor disease, stroke and prevention of re-stenosis after coronary angioplasty is examined and the need for evidence from controlled trials is also discussed.
41. Higashikata T, Mabuchi H. Long-term effect of low-density lipoprotein apheresis in patients with heterozygous familial hypercholesterolemia. Therap Apher Dial 2003; 7:402-407. The authors stress the need for clarification of treatment goals for LDL cholesterol during long-term LDL apheresis.
42. de Gennes JL, Touraine R, Maunand B, et al. [Homozygous cutaneotendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis and heroic treatment]. Bull Mem Soc Med Hop Paris 1967; 118:1377-1402.
43. Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet 1975; 1:1208-1211.
44. Thompson GR, Myant NB, Kilpatrick D, et al. Assessment of long-term plasma exchange for familial hypercholesterolaemia. Br Heart J 1980; 43:680-688.
45. Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange. BMJ (Clin Res Ed) 1985; 291:1671-1673.
46. Lupien PJ, Moorjani S, Awad J. A new approach to the management of familial hypercholesterolaemia: removal of plasma-cholesterol based on the principle of affinity chromatography. Lancet 1976; 1:1261-1265.
47. Stoffel W, Borberg H, Greve V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Lancet 1981; 2:1005-1007.
48. Knisel W, Pfohl M, Muller M, et al. Comparative long-term experience with immunoadsorption and dextran sulfate cellulose adsorption for extracorporeal elimination of low-density lipoproteins. Clin Invest 1994; 72:660-668.
49. Schaumann D, Welch-Wichary M, Voss A, et al. Prospective cross-over comparisons of three low-density lipoprotein (LDL)-apheresis methods in patients with familial hypercholesterolaemia. Eur J Clin Invest 1996; 26:1033-1038.
50. Richter WO, Donner MG, Schwandt P. Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long-term evaluation. Ther Apher 1999; 3:203-208.
51. Schmaldienst S, Banyai S, Stulnig TM, et al. Prospective randomised cross-over comparison of three LDL-apheresis systems in statin pretreated patients with familial hypercholesterolaemia. Atherosclerosis 2000; 151:493-499.
52. Parhofer KG, Geiss HC, Schwandt P. Efficacy of different low-density lipoprotein apheresis methods. Ther Apher 2000; 4:382-385.
53. Bambauer R, Schiel R, Latza R. Low density lipoprotein apheresis: an overview. Ther Apher Dial 2003; 7:382-390. The authors summarize 14 years of experience and more than 4000 apheresis procedures performed on 45 patients with dyslipidaemia and conclude that all currently available systems for LDL apheresis are safe and very effective and have similar frequency of minor (10.9%) and serious - but not life-threatening - (0.3%) side effects.
54. Kajinami K, Mabuchi H. Therapeutic effects of LDL apheresis in the prevention of atherosclerosis. Curr Opin Lipidol 1999; 10:401-406.
55. Otto C, Kern P, Bambauer R, et al. Efficacy and safety of a new whole-blood low-density lipoprotein apheresis system (Liposorber D) in severe hypercholesterolemia. Artif Organs 2003; 27:1116-1122. This study demonstrates that the newest whole-blood LDL apheresis system (Liposorber D) is a safe, simple to use and useful modality to reduce LDL cholesterol.
56. Jansen M, Banyai S, Schmaldienst S, et al. Direct adsorption of lipoproteins (DALI) from whole blood: first long-term clinical experience with a new LDL-apheresis system for the treatment of familial hypercholesterolaemia. Wien Klin Wochenschr 2000; 112:61-69.
57. Napoli C, Ambrosio G, Scarpato N, et al. Decreased low-density lipoprotein oxidation after repeated selective apheresis in homozygous familial hypercholesterolemia. Am Heart J 1997; 133:585-595.
58. Kizaki Y, Ueki Y, Yoshida K, et al. Does the production of nitric oxide contribute to the early improvement after a single low-density lipoprotein apheresis in patients with peripheral arterial obstructive disease? Blood Coagul Fibrinolysis 1999; 10:341-349.
59. Aengevaeren WR, Kroon AA, Stalenhoef AF, et al. Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS). J Am Coll Cardiol 1996; 28:1696-1704.
60. Schuff-Werner P, Schutz E, Seyde WC, et al. Improved haemorheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin-induced extracorporeal LDL precipitation (HELP). Eur J Clin Invest 1989; 19:30-37.
61. Julius U, Siegert G, Gromeier S. Intraindividual comparison of the impact of two selective apheresis methods (DALI and HELP) on the coagulation system. Int J Artif Organs 2000; 23:199-206.
62. Empen K, Otto C, Brodl UC, Parhofer KG. The effects of three different LDL-apheresis methods on the plasma concentrations of E-selectin, VCAM-1, and ICAM-1. J Clin Apheresis 2002; 17:38-43.
63. Motohashi K, Yamane S. The effect of apheresis on adhesion molecules. Therap Apher Dial 2003; 7:425-430.
64. Kojima S, Shida M, Yokoyama H. Changes in C-reactive protein plasma levels during low-density lipoprotein apheresis. Therap Apher Dial 2003; 7:431-434. This small study demonstrates that DSA apheresis reduces the pre-apheresis serum C-reactive protein by more than 50% after repeated treatment. Post-apheresis C-reactive levels were decreased to undetectable levels.
65. Tasaki H. Low-density lipoprotein apheresis in the prevention of recurrent coronary heart disease: a review. Therap Apher Dial 2003; 7:408-412. The author discusses the role of LDL apheresis in CHD prevention and more specifically the role of changes in lipid and non-lipid parameters ('pleiotropic effects') induced by this procedure.
66. Maher VM, Kitano Y, Neuwirth C, et al. Effective reduction of plasma LDL levels by LDL apheresis in familial defective apolipoprotein B-100. Atherosclerosis 1992; 95:231-234.
67. Harada-Shiba M, Tajima S, Yokoyama S, et al. Siblings with normal LDL receptor activity and severe hypercholesterolemia. Arterioscler Thromb 1992; 12:1071-1078.
68. Al Shaikh AM, Abdullah MH, Barclay A, et al. Impact of the characteristics of patients and their clinical management on outcomes in children with homozygous familial hypercholesterolemia. Cardiol Young 2002; 12:105-112.
69. Yamamoto A, Sudo H, Endo A. Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis 1980; 35:259-266.
70. Raal FJ, Pappu AS, Illingworth DR, et al. Inhibition of cholesterol synthesis by atorvastatin in homozygous familial hypercholesterolaemia. Atherosclerosis 2000; 150:421-428.
71. Marais AD, Naoumova RP, Firth JC, et al. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J Lipid Res 1997; 38:2071-2078.
72. Carswell CI, Plosker GL, Jarvis B. Rosuvastatin. Drugs 2002; 62:2075-2085.
73. Marais D, Raal F, Stein E, et al. Effect of rosuvastatin on LDL-cholesterol, melavonic acid, and other lipid measurements in patients with homozygous familial hypercholesterolaemia. In: Posters and abstracts of the 73rd European Atherosclerosis Society Congress. Atherosclerosis Supplements 2002; 3:159.
74. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002; 105:2469-2475.
75. Raal FJ, Marais AD, Klepack E, et al. Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. Atherosclerosis 2003; 171:273-279. This randomized, double-blind, cross-over trial involving 27 patients with homozygous FH showed that avasimibe, an acyl coenzyme A-cholesterol acyltransferase inhibitor, only modestly (by around 4%) enhances the lipid-lowering effect of atorvastatin 80 mg. No significant lipid changes resulted from monotherapy with avasimibe.
76. van Heek M, Farley C, Compton DS, et al. Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats. Br J Pharmacol 2003; 138:1459-1464.
77. Lee HT, Sliskovic DR, Picard JA, et al. Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. Cl-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets. J Med Chem 1996; 39:5031-5034.
78. Marais AD, Blom DJ, Firth JC. Statins in homozygous familial hypercholesterolemia. Curr Atheroscler Rep 2002; 4:19-25.
79. Stefanutti C, Vivenzio A, Colombo C, et al. Treatment of homozygous and double heterozygous familial hypercholesterolemic children with LDL-apheresis. Int J Artif Organs 1995; 18:103-110.
80. Barss V, Phillippe M, Greene MF, Covell L. Pregnancy complicated by homozygous hypercholesterolemia. Obstet Gynecol 1985; 65:756-757.
81. Beigel Y, Hod M, Fuchs J, et al. Pregnancy in a homozygous familial hypercholesterolemic patient treated with long-term plasma exchange. Am J Obstet Gynecol 1990; 162:77-78.
82. Kroon AA, Swinkels DW, van Dongen PW, Stalenhoef AF. Pregnancy in a patient with homozygous familial hypercholesterolemia treated with long-term low-density lipoprotein apheresis. Metabolism 1994; 43:1164-1170.
83. Klingel R, Gohlen B, Schwarting A, et al. Differential indication of lipoprotein apheresis during pregnancy. Therap Apher Dial 2003; 7:359-364. This article summarizes the experience with patients who become pregnant during chronic apheresis (LDL apheresis or plasma exchange), or who were treated during pregnancy by apheresis because of acute disorders of lipid metabolism.
84. Teruel JL, Lasuncion MA, Navarro JF, et al. Pregnancy in a patient with homozygous familial hypercholesterolemia undergoing low-density lipoprotein apheresis by dextran sulfate adsorption. Metabolism 1995; 44:929-933.
85. Starzl TE, Bilheimer DW, Bahnson HT, et al. Heart-liver transplantation in a patient with familial hyperoholesterolaemia. Lancet 1984; 1:1382-1383.
86. Barbir M, Khaghani A, Kehely A, et al. Normal levels of lipoproteins including lipoprotein(a) after liver-heart transplantation in a patient with homozygous familial hypercholesterolaemia. Q J Med 1992; 85:807-812.
87. Offstad J, Schrumpf E, Geiran O, et al. Plasma exchange and heart-liver transplantation in a patient with homozygous familial hypercholesterolemia. Clin Transplant 2001; 15:432-436.
88. Shirahata Y, Ohkohchi N, Kawagishi N, et al. Living-donor liver transplantation for homozygous familial hypercholesterolemia from a donor with heterozygous hypercholesterolemia. Transpl Int 2003; 16:276-279.
89. Keeffe EB. Liver transplantation: current status and novel approaches to liver replacement. Gastroenterology 2001; 120:749-762.
90. Lee LA. Advances in hepatocyte transplantation: a myth becomes reality. J Clin Invest 2001; 108:367-369.
91. Grossman M, Raper SE, Kozarsky K, et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 1994; 6:335-341.
92. Grossman M, Rader DJ, Muller DW, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995; 1:1148-1154.
93. Rader DJ. Gene therapy for familial hypercholesterolemia. Nutr Metab Cardiovasc Dis 2001; 11 (Suppl 5):40-44.
94. Sidhu PS, Naoumova RP, Maher VM, et al. The extracranial carotid artery in familial hypercholesterolaemia: relationship of intimal-medial thickness and plaque morphology with plasma lipids and coronary heart disease. J Cardiovasc Risk 1996; 3:61-67.
95. Hoeg JM, Feuerstein IM, Tucker EE. Detection and quantitation of calcific atherosclerosis by ultrafast computed tomography in children and young adults with homozygous familial hypercholesterolemia. Arterioscler Thromb 1994; 14:1066-1074.
96. Jaeger BR, Tsobanelis T, Bengel F, et al. Long-term prevention of premature coronary atherosclerosis in homozygous familial hypercholesterolemia. J Pediatr 2002; 141:125-128.
97. Summers RM, Choyke PL, Patronas NJ, et al. MR virtual angioscopy of thoracic aortic atherosclerosis in homozygous familial hypercholesterolemia. J Comput Assist Tomogr 2001; 25:371-377.
98. Marais AD, Firth JC, Rose AG, Berger GM. Fatal outcome of homozygous familial hypercholesterolaemia in a black patient: a case report. S Afr Med J 1990; 77:588-590.